QUARATUSUGENE OZEPLASMID CUENTA YA CON DOS STATUS DE LA FDA US PARA EL TRATAMIENTO DE SMALL CELL LUNG CANCER ( CÁNCER DE PULMÓN MICROCÍTICO O DE CÉLULAS PEQUEÑAS ) : *.- ORPHAN DRUG .
*.- FAST TRACK .
Interesante la Combinación Entre ATEZOLIZUMAB Y QUARATUSUGENE OZEPLASMID Para el Mantenimiento de los Pacientes en la Primera Línea ...
*.- Un Ensayo en el Que se Tendran Ya Datos en Febrero 2026 ...
The Combination of QUARATUSUGENE OZEPLASMID and ATEZOLIZUMAB is Being Evaluated as Maintenance Therapy in Patients With ES-SCLC Without Disease Progression On Standard Frontline Therapy With ATEZOLIZUMAB Plus CHEMOTHERAPY in The Ongoing, Open-Label ACCLAIM-3 Trial .
To Be Eligible For Enrollment, Patients Must Have Completed 3 to 4 Cycles of CARBOPLATIN, ETOPOSIDE, and ATEZOLIZUMAB, Achieving Complete Response, Partial Response, or Stable Disease . Upon Enrollment, Patients Will Receive the Combination of ATEZOLIZUMAB and CHEMOTHERAPY as Maintenance Therapy Every 21 Days Until Disease Progression . ...
